Core Insights - Aclaris Therapeutics, Inc. will host its 2025 R&D Day on October 14, 2025, in New York to discuss advancements in immuno-inflammatory disease treatments [1][2] - The event will feature presentations from Aclaris leadership and notable experts in the field, focusing on the company's development of kinase and immune pathway inhibitors [2][6] Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel product candidates for immuno-inflammatory diseases, addressing significant therapeutic gaps [8] - The company has a robust R&D engine and a multi-stage portfolio of product candidates aimed at patients with unmet medical needs [8] Event Details - The R&D Day will include a live question and answer session following the formal presentations, with a webcast available for at least 30 days [3] - Presenters include Dr. Zuzana Diamant and Dr. Michael C. Cameron, who will discuss Aclaris' innovative approaches and therapeutic targets [2][4][5] Research and Development Focus - Aclaris is working on uniquely potent small and large molecule product candidates to fill significant gaps in immuno-inflammatory indications [6] - The company aims to "drug the undruggable" by targeting previously inaccessible components of the kinome and multiple pathways [6] - Updates will be provided on Aclaris' ongoing clinical trials and future clinical program designs [6]